Source: National Science Foundation
For general correspondence, please email bigdata@nsf.gov.
The Core Techniques and Technologies for Advancing Big Data Science & Engineering (BIGDATA) solicitation aims to advance the core scientific and technological means of managing, analyzing, visualizing, and extracting useful information from large, diverse, distributed and heterogeneous data sets so as to: accelerate the progress of scientific discovery and innovation; lead to new fields of inquiry that would not otherwise be possible; encourage the development of new data analytic tools and algorithms; facilitate scalable, accessible, and sustainable data infrastructure; increase understanding of human and social processes and interactions; and promote economic growth and improved health and quality of life. The new knowledge, tools, practices, and infrastructures produced will enable breakthrough discoveries and innovation in science, engineering, medicine, commerce, education, and national security -- laying the foundations for US competitiveness for many decades to come.
The phrase "big data" in this solicitation refers to large, diverse, complex, longitudinal, and/or distributed data sets generated from instruments, sensors, Internet transactions, email, video, click streams, and/or all other digital sources available today and in the future.
Source: NIH Office of Extramural Research
Weiniu Gan, Ph.D.
Division of Lung Diseases
National Heart, Lung and Blood Institute
6701 Rockledge Dr. MSC 7952
Bethesda, Maryland 20892-7952
Telephone: (301) 435-0202
Email: ganw2@nhlbi.nih.gov
Antonello Punturieri, M.D., Ph.D.
Division of Lung Diseases
National Heart, Lung, and Blood Institute
Two Rockledge Centre, Room 10146
6701 Rockledge Drive
Bethesda, MD 20892-7952
Telephone: (301) 435-0230
Fax:(301)-480-5577
Email:punturieria@nhlbi.nih.gov
The National Heart, Lung, and Blood Institute (NHLBI) invites applications to: (1) generate systems-level models of pulmonary pathobiology through integrative analyses of existing omics (e.g., genomics, transcriptomics, proteomics, metabolomics) data; and (2) experimentally test novel predictions of these models using human tissues/cells and/or mammalian animal models.
Source: NIH Office of Extramural Research
Tony Dickherber, Ph.D.
Center for Strategic Scientific Initiatives, Office of the Director
National Cancer Institute, NIH
31 Center Drive, Room 10A-33
Bethesda, MD 20892
Telephone: 301-827-4374
Email: dickherberaj@mail.nih.gov
This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), solicits grant applications proposing research projects on the advanced development of emerging molecular and cellular analysis technologies through technical/analytical validation in an appropriate cancer-relevant biological system or context. An emerging technology is defined as one that has passed the pilot developmental stage and shows promise, but has not yet been evaluated within the context of its intended use. If successful, these technologies would accelerate research in cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. This FOA solicits projects where proof-of-principle of the proposed technology or methodology has been established and supportive preliminary data are available. Projects proposed to this FOA should reflect the potential to produce a major impact in a broad area of cancer-relevant research. Projects proposing to use established technologies where the novelty resides in the biological or clinical question being pursued are not appropriate for this solicitation as non-responsive and will not be reviewed.
This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
For more information click here.
Source: NIH Office of Extramural Research
Tony Dickherber, Ph.D.
Center for Strategic Scientific Initiatives, Office of the Director
National Cancer Institute, NIH
31 Center Drive, Room 10A-33
Bethesda, MD 20892
Telephone: 301-827-4374
Email: dickherberaj@mail.nih.gov
This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), solicits grant applications proposing technically innovative feasibility studies focused on early stage development of technologies that address issues related to pre-analytical variations in the collection, processing, handling, and storage of cancer-relevant biospecimens or their derivatives. The overall goal is to develop technologies capable of interrogating and/or maximizing the quality and utility of biospecimens or samples derived from those biospecimens for downstream molecular analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to assess sample quality, preserve/protect sample integrity, and establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to potentially accelerate and/or enhance research in cancer biology, prevention, diagnosis, treatment, epidemiology, and cancer health disparities, by reducing pre-analytical variations that affect biospecimen and/or sample quality. All projects must include quantitative milestones (i.e. technical metrics that determine whether the specific aims have been accomplished).
This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
For more information click here.
Source: NIH Office of Extramural Research
Tony Dickherber, Ph.D.
Center for Strategic Scientific Initiatives, Office of the Director
National Cancer Institute, NIH
31 Center Drive, Room 10A-33
Bethesda, MD 20892
Telephone: 301-827-4374
Email: dickherberaj@mail.nih.gov
This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), solicits grant applications proposing technically innovative feasibility studies focused on the advanced development and validation of cancer-relevant technologies that address issues related to pre-analytical variations in the collection, processing, handling, and storage of biospecimens or their derivatives. The overall goal is to develop technologies capable of interrogating and/or maximizing the quality and utility of biospecimens or their derived samples for downstream molecular analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to assess sample quality, preserve/protect sample integrity, and establish verification criteria for quality assessment/quality control and handling under diverse conditions. This FOA solicits R33 applications; this mechanism is suitable for projects where proof-of-principle of the proposed technology or methodology has already been established and supportive preliminary data are available. Projects proposing to use established technologies where the novelty resides in the biological or clinical question being pursued are not appropriate for this solicitation as non-responsive and will not be reviewed.
This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Source: NIH Office of Extramural Research
Tony Dickherber, Ph.D.
Center for Strategic Scientific Initiatives, Office of the Director
National Cancer Institute, NIH
31 Center Drive, Room 10A33
Bethesda, MD 20892
Telephone: 301-827-4374
Email: dickherberaj@mail.nih.gov
This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), solicits grant applications proposing exploratory research projects focused on the inception and development of early stage, highly innovative, technologies or emerging technologies with significant transformative potential that has not yet been explored in a cancer-relevant use. An emerging technology is defined (for the purpose of this FOA) as one that has passed the initial developmental stage, but has not yet been evaluated within the context of a cancer-relevant intended use and requires significant modification for the proposed application. The emphasis of this FOA is on technologies with a high degree of technical innovation with the potential to significantly affect and transform investigations exploring the molecular and cellular bases of cancer. If successful, these technologies would accelerate and/or enhance research in the areas of cancer biology, prevention, diagnosis and treatment, control, epidemiology, and/or cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be based on molecular and/or cellular characterizations of cancer.
This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
For more information click here.